Status: Recruiting

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

Participants needed: 411

Trial details

Phase: Phase 1Age: 12-85Biological sex: AllType: InterventionalSponsor: Inhibrx Biosciences, IncUpdated: Sep 8, 2026Locations: 37

Eligibility criteria

Males or females aged ≥12 to less than 85 years for Ewing sarcoma and 18 to less... [+8]

Prior treatment with or exposure to DR5 agonists. [+17]

Status: Recruiting

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

Participants needed: 340

Trial details

Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Inhibrx Biosciences, IncUpdated: Jul 29, 2026Locations: 42

Eligibility criteria

Males or females aged ≥18 years. [+9]

Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or... [+14]

Clinical trials

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)